BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer

Giuseppe Bronte, Antonio Russo, Edgardo S Santos, Kostantinos Papadimitriou, Christian Rolfo, Luis E Raez, Jan P Van Meerbeeck, Lucio Buffoni

Risultato della ricerca: Article

21 Citazioni (Scopus)

Abstract

INTRODUCTION:Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy.AREAS COVERED:Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors present here nintedanib (BIBF 1120), a triple angiokinase inhibitor. It targets not only VEGFRs, but also FGFR and PDGFR. All the available clinical information regarding Phase I - II trials and the toxicity and efficacy of BIBF 1120 both as single agent and in combination with cytotoxic agents in non-small cell lung cancer (NSCLC) is reviewed and discussed here.EXPERT OPINION:Up till now, Phase I and II trials with nintedanib showed an improvement for survival of advanced NSCLC patients. Tolerability profile seems to be acceptable in these clinical trials. However, Phase III trials are mandatory to translate these findings into clinical practice. The research for predictive biomarkers could improve the success of these anti-angiogenic agents.
Lingua originaleEnglish
pagine (da-a)1081-1088
Numero di pagine8
RivistaExpert Opinion on Investigational Drugs
Volume22
Stato di pubblicazionePublished - 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Vascular Endothelial Growth Factor A
Neoplasms
Cytotoxins
Therapeutics
Biomarkers
Monoclonal Antibodies
Clinical Trials
Neoplasm Metastasis
Survival
nintedanib
Research
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cita questo

BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. / Bronte, Giuseppe; Russo, Antonio; Santos, Edgardo S; Papadimitriou, Kostantinos; Rolfo, Christian; Raez, Luis E; Van Meerbeeck, Jan P; Buffoni, Lucio.

In: Expert Opinion on Investigational Drugs, Vol. 22, 2013, pag. 1081-1088.

Risultato della ricerca: Article

Bronte, G, Russo, A, Santos, ES, Papadimitriou, K, Rolfo, C, Raez, LE, Van Meerbeeck, JP & Buffoni, L 2013, 'BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer', Expert Opinion on Investigational Drugs, vol. 22, pagg. 1081-1088.
Bronte, Giuseppe ; Russo, Antonio ; Santos, Edgardo S ; Papadimitriou, Kostantinos ; Rolfo, Christian ; Raez, Luis E ; Van Meerbeeck, Jan P ; Buffoni, Lucio. / BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. In: Expert Opinion on Investigational Drugs. 2013 ; Vol. 22. pagg. 1081-1088.
@article{50403772cf0c421e9db316a22d89d351,
title = "BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer",
abstract = "INTRODUCTION:Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy.AREAS COVERED:Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors present here nintedanib (BIBF 1120), a triple angiokinase inhibitor. It targets not only VEGFRs, but also FGFR and PDGFR. All the available clinical information regarding Phase I - II trials and the toxicity and efficacy of BIBF 1120 both as single agent and in combination with cytotoxic agents in non-small cell lung cancer (NSCLC) is reviewed and discussed here.EXPERT OPINION:Up till now, Phase I and II trials with nintedanib showed an improvement for survival of advanced NSCLC patients. Tolerability profile seems to be acceptable in these clinical trials. However, Phase III trials are mandatory to translate these findings into clinical practice. The research for predictive biomarkers could improve the success of these anti-angiogenic agents.",
author = "Giuseppe Bronte and Antonio Russo and Santos, {Edgardo S} and Kostantinos Papadimitriou and Christian Rolfo and Raez, {Luis E} and {Van Meerbeeck}, {Jan P} and Lucio Buffoni",
year = "2013",
language = "English",
volume = "22",
pages = "1081--1088",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer

AU - Bronte, Giuseppe

AU - Russo, Antonio

AU - Santos, Edgardo S

AU - Papadimitriou, Kostantinos

AU - Rolfo, Christian

AU - Raez, Luis E

AU - Van Meerbeeck, Jan P

AU - Buffoni, Lucio

PY - 2013

Y1 - 2013

N2 - INTRODUCTION:Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy.AREAS COVERED:Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors present here nintedanib (BIBF 1120), a triple angiokinase inhibitor. It targets not only VEGFRs, but also FGFR and PDGFR. All the available clinical information regarding Phase I - II trials and the toxicity and efficacy of BIBF 1120 both as single agent and in combination with cytotoxic agents in non-small cell lung cancer (NSCLC) is reviewed and discussed here.EXPERT OPINION:Up till now, Phase I and II trials with nintedanib showed an improvement for survival of advanced NSCLC patients. Tolerability profile seems to be acceptable in these clinical trials. However, Phase III trials are mandatory to translate these findings into clinical practice. The research for predictive biomarkers could improve the success of these anti-angiogenic agents.

AB - INTRODUCTION:Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy.AREAS COVERED:Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors present here nintedanib (BIBF 1120), a triple angiokinase inhibitor. It targets not only VEGFRs, but also FGFR and PDGFR. All the available clinical information regarding Phase I - II trials and the toxicity and efficacy of BIBF 1120 both as single agent and in combination with cytotoxic agents in non-small cell lung cancer (NSCLC) is reviewed and discussed here.EXPERT OPINION:Up till now, Phase I and II trials with nintedanib showed an improvement for survival of advanced NSCLC patients. Tolerability profile seems to be acceptable in these clinical trials. However, Phase III trials are mandatory to translate these findings into clinical practice. The research for predictive biomarkers could improve the success of these anti-angiogenic agents.

UR - http://hdl.handle.net/10447/100244

UR - http://informahealthcare.com/doi/abs/10.1517/13543784.2013.812630

M3 - Article

VL - 22

SP - 1081

EP - 1088

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

ER -